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Collapsing glomerulopathy in HIV and non-HIV patients: A late 1970s, a new type of renal injury emerged. AIDS-
clinicopathological and follow-up study. associated nephropathy, characterized by focal and seg-
Background. Collapsing glomerulopathy (CG) is a pattern mental glomerulosclerosis (FSGS) with massive protein-of renal injury that is seen in association with HIV infection
uria and rapid progression to end-stage renal diseaseand that is increasingly recognized in non-HIV patients.
(ESRD), was recognized as a frequent pattern of renalMethods. A review of native kidney biopsies with CG that
were diagnosed between 1979 and 1997 in 18 HIV and 42 non- disease in these patients [1, 2]. Other studies confirmed
HIV patients is provided. unique clinical and pathologic features of this condition,
Results. HIV and non-HIV patients with CG were similar and eventually, it became known as HIV-associated ne-in terms of age, sex ratio, serum creatinine, proteinuria, the
phropathy (HIVAN), emphasizing the collapsing fea-extent of collapsing and sclerosing glomerular lesions, and in-
terstitial damage. A slight female predominance was found in tures of glomerular damage along with frequent tubular
both groups. In contrast to non-HIV patients, the HIV group and interstitial involvement by severe degenerative and
was characterized by a high prevalence of blacks (94 vs. 57%), inflammatory changes [3–10]. HIVAN has also been re-
frequent tubuloreticular inclusions (76 vs. 29%), and microcystic
garded by some authors to have certain distinct featurestubular changes (72 vs. 40%). In 13 non-HIV patients, CG was
compared with heroin-associated nephropathy (HAN)associated with a systemic lupus erythematosus (SLE)-like dis-
ease (5), hepatitis C virus (HCV) infection (3), HTLV-I infec- [1, 3, 7, 9, 11]. Furthermore, although HIVAN initially
tion, MCTD, acute monoblastic leukemia, multiple myeloma, appeared to be associated with intravenous drug abuse
and cerebral arteritis. Overall, the renal survival of human (IVDA) as a mode of HIV transmission, later observa-immunodeficiency virus (HIV) and non-HIV patients with CG
tions revealed that this association was due to a highwas not significantly different. Cox regression revealed that
prevalence of blacks with HIVAN rather than to IVDAHIV infection had an adverse effect on short-term renal sur-
vival, with other significant risk factors being extensive intersti- itself [3, 4, 12–14].
tial fibrosis, high serum creatinine, proteinuria, and a low per- In 1986, Weiss et al reported six patients with rapidly
centage of glomeruli with collapse. The slope of reciprocal
progressive nephrotic syndrome and glomerular capil-creatinine was best predicted by the degree of proteinuria.
lary collapse [15]. Because only one of these patientsSerum creatinine correlated with the extent of interstitial fi-
brosis, the male gender, and the percentage of glomeruli with subsequently developed AIDS, these authors suggested
collapse. Proteinuria was best predicted by the extent of efface- that this condition may represent a new clinicopathologi-
ment of podocyte foot processes. cal entity. As a matter of fact, pathologic features of thisConclusions. CG shares many clinicopathological similari-
entity closely resembled the pathology of HIVAN [9].ties in HIV and non-HIV patients. In some non-HIV patients,
Later studies confirmed the existence of collapsing glom-CG was associated with autoimmune diseases, lymphoprolifer-
ative disorders, and viral infections. erulopathy (CG) independent of HIV infection (no evi-
dence of HIV-1 infection or risk factors for HIV) [16–18].
These studies also showed that CG represents an aggres-
With the advance of the epidemic of acquired immu- sive form of renal disease when compared with the more
nodeficiency syndrome (AIDS) in the Western world in classic histological type of idiopathic focal segmental glo-
merulosclerosis (FSGS).
Although the existence of idiopathic CG independentKey words: acquired immunodeficiency syndrome, progressive renal
disease, glomerulosclerosis, human immunodeficiency virus, infection. of HIVAN, HAN, and classic idiopathic FSGS is well
recognized, it remains unclear what factors contributeReceived for publication March 31, 1999
to the occurrence of this form of glomerular injury andand in revised form July 12, 1999
Accepted for publication July 19, 1999 why this renal condition seems to have emerged in paral-
lel to the epidemic of HIV-1 infection. It is also unclear 1999 by the International Society of Nephrology
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whether idiopathic CG has distinct demographic, clini- HIV test performed with respect to the renal biopsy was
variable: Six patients tested positive before the biopsy,cal, pathological, and prognostic features when com-
pared with HIVAN. Therefore, we designed our study five at the time of biopsy, and seven after the biopsy
findings suggested the possibility of HIV infection. Theto investigate the whole spectrum of CG as a pattern of
renal injury, and to contrast features of this condition in patients diagnosed as being HIV positive after the biopsy
were also considered as having CG associated with HIVpatients with and without HIV infection.
infection.
Non-HIV patients were defined as either having nega-
METHODS
tive HIV test results (36 patients) or not having risk factors
Material for HIV infection and not having developed features of
AIDS during the follow-up period (6 patients). EighteenRenal biopsies received by the Department of Pathol-
ogy of the Brigham and Women’s Hospital (BWH) from of the 36 HIV-1–negative patients also tested negative
for HIV-2.1979 to January 1997 with established or potential diag-
nosis of CG regardless of patients’ HIV status were identi- Three patients were excluded from further analysis be-
cause of inadequate information to define the HIV status.fied. These biopsies were then re-examined, and the cases
were classified as CG when focal segmental and/or global Risk factors for HIV infection were defined as history
of IVDA, male homosexuality, or engaging in unpro-collapse of the glomerular capillary tuft was present, as
described previously [15–17]. At least one glomerulus tected sex known before or after the diagnosis of CG.
with characteristic features of segmental or global capil-
Statistical methodslary collapse, with wrinkling of the basement membrane,
prominence and crowding of the epithelial cells, and Groups were compared using Fisher’s exact test for
dichotomous data, Wilcoxon rank-sum tests for ordinalfrequent protein reabsorption droplets, was required for
the diagnosis of CG. The results of immunofluorescence data, and t-tests for approximately normally distributed
data. Multiple regression was used to develop models tomicroscopy and electron microscopy were again re-
viewed, and some electron microscopy specimens were predict proteinuria, serum creatinine, and the slope of
reciprocal creatinine. Product-limit estimates were usedre-examined when necessary. A total of 63 native kidney
biopsies reviewed satisfied the diagnostic criteria for CG. to summarize renal survival data, and the log rank test
was used for comparing renal survival distributions [19].Light microscopy slides that were examined contained
at least 6 glomeruli per section (median of 17). The Renal death was defined as the initiation of permanent
renal replacement therapy, and renal survival was de-percentage of globally/segmentally collapsed and glob-
ally sclerosed glomeruli was calculated. The presence of fined as the time from renal biopsy to renal death. Cox
proportional hazards analysis was used to develop a mul-tubular casts with microcystic dilation was noted. The
degree of active interstitial inflammation and interstitial tiple variable model to predict the time to renal death
[20]. A combination of forward, backward, and stepwisefibrosis was estimated as a percentage of the cortical
area involved. The degree of effacement or “fusion” of procedures was used to arrive at the final model [21]. A
term representing the interaction of HIV status and timeglomerular epithelial cell foot processes was estimated
semiquantitatively as focal for ,50%, extensive for 50 to was added to the model after observing that the hazard
ratio for HIV was not constant. The rate of progression of80%, and diffuse for .80% of the glomerular capillaries
revealing this feature. The presence of tubuloreticular renal insufficiency was defined as the slope of reciprocal
serum creatinine, produced by best-fit regression analysisinclusions (TRIs) was noted in the glomerular endothe-
lial cells. using an inverse creatinine as the dependent variable
and the time of the measurement of the serum creatinineClinical information on the patient at the time of the
biopsy as well as follow-up data was obtained from the as an independent variable (minimum of 4 time points).
Numerical variables are represented as the arithmeticbiopsy record, clinical histories, and questionnaires sub-
mitted to the nephrologists following the patients. Data mean 6 sd.
on testing for HIV were also retrieved under authorized
permission from the Department of Laboratory Medi-
RESULTS
cine of BWH. Information on some patients’ human
Comparison of demographic, clinical, and pathologicallymphocyte antigen (HLA) phenotype was available at
characteristics of collapsing glomerulopathy in HIVthe Immunogenetics Laboratory at BWH.
and non-HIV patientsPatients were defined as HIV positive according to the
results of HIV-1 and HIV-2 serologic testing. Seventeen A slight predominance of female sex was observed in
both groups (Table 1). The male-to-female ratio was 0.80patients tested positive for HIV-1, and one patient was
found to have HIV-2 infection. Eight HIV-1–positive and 0.83 in the HIV and non-HIV groups, respectively.
There was a significant predominance of blacks in thepatients tested negative for HIV-2. The time of positive
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Table 3. Clinical characteristics of CG in HIV and non-HIV patientsTable 1. Demographics of collapsing glomerulopathy (CG) in HIV
and non-HIV patients
Characteristic HIV N Non-HIV N P value
HIV Non-HIV
Time to biopsy months,(N 5 18) (N 5 42) P value
median 0.75 17 1 38 0.6a
Proteinuria at biopsy g/day,Gender % female 56% 55% 1.0a
Race % black 94% 57% 0.005a median 8.7 17 11.8 36 0.2a
Serum creatinine at biopsyAge at biopsy median (range) 36.0 (26–70) 38.5 (13–77) 0.5b
mg/dl, median 3.5 17 2.9 40 0.2aa By Fisher’s exact test
Creatinine .2.0 mg/dl, atb By Wilcoxon rank sum analysis
biopsy, % 76% 17 70% 40 0.8b
Nephrotic proteinuria at
presentation 78% 18 89% 38 0.3b
Renal failure at
Table 2. Prevalence of identified risk factors in HIV presentation 72% 18 74% 38 1.0b
and non-HIV patients Hypertension at
presentation 6% 18 29% 38 0.004b
HIV Non-HIV Flu-like illness at
(N 5 18) (N 5 42) P value presentation 14% 14 26% 38 0.5b
Vomiting at presentation 14% 14 29% 38 0.5bHistory of any potential risk
Diarrhea at presentation 21% 14 11% 38 0.4bfactor for HIV 72% 19% 0.0002
Fever at presentation 50% 14 16% 38 0.026bIVDA 44% 12% 0.013
Loss of weight atMale homosexual 11% 2% 0.2
presentation 29% 14 11% 38 0.2bHistory of unprotected sex 17% 5% 0.15
a By Wilcoxon rank sum analysisIVDA is intravenous drug abuse. P values are by Fisher’s exact test.
b By Fisher’s exact test
HIV group (94%) compared with the non-HIV group
were positive for anticardiolipin antibodies (N 5 6), lu-(57%, P , 0.005). The only non-black HIV patient was
pus anticoagulant (N 5 3), or ANCA (N 5 17).of Hispanic ethnicity, and 5 of the 18 white non-HIV
Of the 18 HIV-positive patients, 2 also were positivepatients were Hispanics. Six of the HIV and eight of
for hepatitis B-s-antigen (HBsAg), and 2 were positivenon-HIV patients were also identified as descendents
for antibodies against hepatitis C virus (HCV), poten-from inhabitants of the Caribbean islands. The mean age
tially contracted before the initiation of dialysis.of the HIV and non-HIV patients was 37.0 6 10.5 and
In the non-HIV group, three White patients with a37.8 6 14.2 years, respectively.
history of IVDA were positive for HCV (2 before theThe history of potential risk factors for HIV was more
biopsy, and 1 after the biopsy but before initiation offrequently identified in HIV patients (72 vs. 19% in the
dialysis). One of these three HCV-positive patients wasnon-HIV group, P 5 0.0002; Table 2). All of the non-
also found to have TRIs on biopsy; nevertheless, he hadHIV patients with a history of risk factors tested negative
twice tested negative for HIV-1 and once for HIV-2.(most of them repeatedly) for HIV.
Two black intravenous drug abusers were found to beThe mean duration of renal disease before the biopsy
HCV positive while on dialysis (the test for HCV waswas 3.3 6 5.2 and 2.3 6 2.7 months in HIV and non-
not available at the time of the biopsy). As a matter ofHIV patients, respectively (Table 3). At the time of the
fact, all of the five non-HIV patients with a history ofbiopsy, the daily urinary protein excretion was on aver-
IVDA were HCV positive. Twenty-three patients testedage 10.3 6 8.5 and 13.3 6 10.6 g/24 hr, and serum creati-
negative for HCV. Thirty-one patients tested negativenine was 6.0 6 5.9 and 5.4 6 5.3 mg/dl in HIV and non-
for HBsAg. Two of them became HBsAg positive afterHIV groups, respectively. Similarly, frequencies of main
they had developed ESRD. One patient of Haitian originrenal and nonrenal manifestations of the disease were
with repeatedly negative HIV tests and no identifiednot significantly different between the two groups, except
risk factors for HIV was found to have human T cellhigher incidence of reported arterial hypertension in
lymphotropic virus-1 (HTLV-I) infection.non-HIV patients and higher incidence of fever in HIV
Several patients in the non-HIV group had other medi-patients (Table 3).
cal conditions that by clinical setting could be potentiallyThe results of serological tests were available in a
associated with their renal disease. Five black ANA-posi-subset of patients. None of the HIV patients revealed
tive female patients (including 3 patients with anti-DNAa positive anti-nuclear antibody (ANA) test (N 5 7),
antibodies) had clinical manifestations characterized aswhereas 10 of 31 non-HIV patients showed a positive
a systemic lupus erythematosus (SLE)-like disorder; how-ANA screening test at titers higher than 1:40. Three of
ever, none of them had an established diagnosis of SLE.the ANA-positive patients also had anti–double-stranded
One Hispanic male patient had been diagnosed withDNA antibodies. Two non-HIV patients were positive
for rheumatoid factor (N 5 13). No patients, when tested, mixed connective tissue disease. One Caucasian female
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Table 5. Multiple variable models to predict serum creatinine andTable 4. Pathology findings on biopsy
daily proteinuria at biopsy
HIV Non-HIV
(N 5 18) (N 5 42) P value Model or Parameter Standard
partial R2 estimate error P value
Mean % of glomeruli with
collapsing lesions 45.8636.2 40.5 629.4 0.6a Prediction of serum
creatinine (N 5 55) 0.71 0.0001Mean % of globally sclerosed
glomeruli 16.0617.4 20.5 628.1 0.5a % Interstitial fibrosis 0.53 0.05 0.02 0.0031
Male gender 0.13 3.76 0.99 0.0004Mean % of affected (collapsed/
globally sclerosed) glomeruli 61.8638.5 61.0 630.9 0.9a % Glomeruli with
collapsing lesions 0.05 0.04 0.01 0.0051Mean % of renal cortex with
interstitial inflammation 27.2622.7 25.2 626.7 0.8a Prediction of 24-hour
proteinuria (N 5 45) 0.65 0.0001Mean % of renal cortex with
interstitial fibrosis 34.2624.6 30.6 633.4 0.7a Fusion of podocyte foot
processes 0.61 5.81 1.41 0.0002Marked cast nephropathy 72% 40% 0.047b
TRIs in glomerular Patient’s age 0.04 0.11 0.05 0.0271
endothelial cells 76%c 29%e 0.0014b
Diffuse effacement of
podocyte foot processes 57%d 38%f 0.342b
a By unpaired t-test
b By Fisher’s exact test As HIV testing was frequently performed after the
c N 5 17 renal biopsy, prompted by the diagnosis of CG, we ques-d N 5 14
e N 5 38 tioned the predictive value of the morphologic features
f N 5 37 of CG seen on biopsy with respect to the patient’s HIV
status known either before or after the biopsy. The sensi-
tivity of TRIs for prediction of HIV infection was 0.76,
and the specificity was 0.71, with a positive predictivehad multiple myeloma at the time of renal biopsy, which
value of 0.54 in all patients with CG. Similarly, the pres-revealed CG but no paraprotein deposition. One African
ence of casts in the tubules with microcystic dilation hadAmerican male died of acute monoblastic leukemia. One
a sensitivity of 0.72 and a specificity of 0.6.13-year-old Puerto Rican boy died of granulomatous
Data on human lymphocyte antigen (HLA)-A and(giant cell) cerebral arteritis confirmed by autopsy find-
HLA-B frequencies were available on 13 black patientsings. All of these patients developed ESRD during the
(2 of them were HIV patients) and 7 white (all non-follow-up period except two patients with SLE-like dis-
HIV) patients. HLA-DR antigens were identified in 12orders, who died because of complications of their sys-
black and 7 white patients, respectively. The statisticaltemic disease.
significance of prevalence of individual antigens in ourLight microscopy findings were strikingly similar in
patients was tested by comparison to the antigen fre-both groups (Table 4), except for a significant predomi-
quencies in reference population, recalculated [2 * (genenance of microcystic tubular dilation with casts in HIV
frequency) 2 (gene frequency)2] from HLA gene fre-patients (72 vs. 40% in non-HIV, P 5 0.045). Interstitial
quencies available in the literature [22]. Although ob-inflammation affected 20% or more of the renal cortex
served HLA antigen frequencies did not differ signifi-in 61% HIV and 49% non-HIV patients, whereas inter-
cantly from the control population after a correction ofstitial fibrosis of more than 20% was seen in 71% of
P values by the conservative method of Bonferroni forHIV and 46% of non-HIV patients. Cellular crescent
multiple comparisons, relatively high frequencies offormation was seen in one HIV and nine non-HIV pa-
HLA-B18 (23%) and HLA-DR10 (25%) in blacks andtients. The incidence of TRIs in the glomerular endothe-
HLA-B44 (71%) and HLA-DR4 (57%) in whites werelial cells found by electron microscopy was significantly
noted. Interestingly, all white patients had either HLA-higher in the HIV group (76 vs. 29% in non-HIV, P 5
B44 or HLA-DR4 or both antigens.0.0014). The effacement of podocyte foot processes was
estimated as diffuse in only 57 and 38% of the HIV and
Clinical and pathological correlatesnon-HIV patients, respectively. In addition to morpho-
Clinical and morphological predictors of serum creati-logical findings diagnostic of CG, three cases also re-
nine and daily proteinuria at the time of biopsy werevealed features of membranous nephropathy and one
investigated by multiple regression analysis (Table 5).case of IgA nephropathy in the non-HIV group, which
The final model to predict serum creatinine at the timeby morphologic and clinical criteria were interpreted as
of the biopsy included the extent of interstitial fibrosis,a chronic underlying glomerular disease with superim-
the percentage of glomeruli with collapsing lesions, andposed CG. Interestingly, follow-up of these four patients
male gender (model P 5 0.0001). Daily urinary proteinshowed a rather fast progression of renal insufficiency,
excretion was best predicted by the extent of effacementnot characteristic for the underlying glomerular diseases
but in keeping with the diagnosis of CG. foot processes and the patient’s age (model P 5 0.0002).
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Table 6. Cox model to predict renal survival in patients with CG
Hazard 95% confidence
ratio interval P value
Model 0.0001
% Interstitial fibrosis .20% 7.48 (2.73, 20.52) 0.0001
Serum creatinine .2.0 mg/dl 5.79 (2.03, 16.48) 0.001
Proteinuria .8 g/day 2.95 (1.24, 6.98) 0.014
% Glomeruli with collapsing
lesions .20% 0.26 (0.10, 0.65) 0.004
HIV infection 5.94 (1.68, 21.02) 0.0057
Interaction between HIV
infection and time (months)
after biopsy 0.92 (0.88, 0.97) 0.0005
for HIV and non-HIV patients without accounting for
other potentially predictive variables (P 5 0.28). The
product limit estimate for the median renal survival was
5.8 and 15.7 months in HIV and non-HIV patients, re-
spectively. The estimated event rates at 24 months were
33 and 41% for HIV and non-HIV patients, respectively.
A multiple variable model was developed to account
simultaneously for potentially important clinical, demo-
graphic, and morphologic features. Potential predictorsFig. 1. Probability of renal survival of HIV (– – – –) and non-HIV
patients (———) with collapsing glomerulopathy (CG). The number that were tested were patient’s gender, age, race, risk for
of patients remaining is shown in parentheses. HIV, HIV status, interaction between HIV status and
months after biopsy, time from manifestation of the dis-
ease to biopsy, serum creatinine at biopsy .2.0 mg/dl,
proteinuria at biopsy .8.0 g/day, the percentage of glo-Clinical course and outcome
meruli with collapsing lesions .20%, the percentage of
The duration of follow-up after the biopsy was 14.0 6 globally sclerosed glomeruli .20%, the extent of active
18.6 months in HIV patients (range 0 to 62 months, interstitial inflammation .20%, the extent of interstitial
median 5.5) and 21.4 6 23.6 months in non-HIV patients fibrosis .20%, the presence of tubular casts with micro-
(range 0 to 91 months, median 10.5), respectively (P 5 cystic dilation, and the presence of TRIs in endothelial
0.24). During the follow-up period, 14 (77.8%) HIV and cells. The final model shown in Table 6 significantly pre-
30 (71.4%) non-HIV patients developed ESRD (P 5 dicted renal death (P 5 0.0001). This model shows that
0.6). In the group of patients with functioning kidneys the risk of renal death was significantly increased by
at the end of follow-up, serum creatinine .2.0 mg/dl was interstitial fibrosis .20%, serum creatinine .2.0 mg/dl,
observed in 2 of 4 HIV and 6 of 12 non-HIV patients. proteinuria . 8 g/day, and HIV infection and was de-
During the total follow-up period (including time on creased by a frequency of glomeruli with collapsing le-
dialysis in some patients, median 16 and 36 months in sions .20%. Consideration of the HIV term and the
HIV and non-HIV patients, respectively), nine HIV and interaction term together shows that the effect of HIV
seven non-HIV patients died. Most of the patients (7 infection was to increase the risk of renal death nearly
HIV and 4 non-HIV) were on renal replacement therapy sixfold at biopsy, but this effect diminished during follow-
at the time of death, whereas two HIV and three non- up. In addition, interstitial fibrosis (P 5 0.0001) and serum
HIV patients had variable degrees of renal insufficiency; creatinine (P 5 0.0008), as single predictors, were signifi-
however, the cause of death in these patients was not cantly associated with earlier renal death in product-limit
directly related to the complications of their renal dis- analysis (Figs. 2 and 3).
ease. One HIV patient and eight non-HIV patients re- Potential clinical, demographic, and pathological pre-
ceived a renal allograft. The recurrence of CG was diag- dictors of progression of renal failure, including HIV
nosed in one non-HIV patient six months after she status, were also investigated by multiple regression anal-
received a living-related allograft from her son (this case ysis where the patient’s slope of the reciprocal creatinine
was the subject of a case report) [23]. was used as the response variable. The rate of decline
The significance of HIV status to predict renal survival of renal function correlated significantly with daily pro-
was tested by product-limit analysis (18 HIV and 42 non- teinuria at biopsy (N 5 33, P 5 0.002), accounting for
HIV patients). There were 44 events. Figure 1 shows 27% of the variance.
Data on therapy were available on 37 non-HIV patients.that the time to renal death was not significantly different
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Fig. 3. Probability of renal survival of collapsing glomerulopathy (CG)Fig. 2. Probability of renal survival of collapsing glomerulopathy (CG) patients with serum creatinine at the time of the biopsy of .2 mg/dlpatients with interstitial fibrosis .20% (– – – –) and #20% (———). (– – – –) and #2 mg/dl (———). The number of patients remaining is
The number of patients remaining is shown in parentheses. shown in parentheses.
Twenty-three non-HIV patients were treated with ste-
HIV CG cases diagnosed during the period from 1979roids. Two of them responded well to the therapy and
had normal renal function at the end of the follow-up to the beginning of 1997. It seems meaningful that ap-
period. Seven patients revealed partial response of their proximately two thirds of renal biopsies with this pattern
nephrotic syndrome or renal failure, as defined by the of renal injury, once thought to be rather specific for HIV
treating nephrologist (some became steroid-dependent). patients [8], were found in non-HIV patients. Furthermore,
Only two of them had normal serum creatinine at the during the same period, CG was being increasingly recog-
end of the follow-up, whereas one had chronic renal nized in non-HIV patients: only 6 of 18 HIVAN but as
failure, and four patients had reached ESRD. Fourteen many as 39 of 42 non-HIV CG cases were diagnosed
patients were steroid-resistant, and only three of them after 1989 (data not shown). This evidence is also in
had some renal function remaining at the end of follow- keeping with the notion of an increasing incidence of
up, however, with serum creatinine .2.0 mg/dl.
idiopathic CG [17]; however, this trend was not observedSix non-HIV patients also received cytostatic therapy,
by others [18].which, in general, did not seem to ameliorate their ne-
In our study, we applied a phenomenological approachphrotic syndrome, although two of these patients had
to this relatively new clinicopathologic entity of CG innormal serum creatinine at the end of follow-up, whereas
that morphologic evidence of CG and adequate informa-all others developed ESRD. Three patients were also
tion on the patient’s HIV status were the only inclusiontreated with cyclosporine A: Two of them did not respond
criteria for the study. This allowed us to include theto the therapy and developed ESRD. One patient devel-
oped “cyclosporine-dependent” nephrotic syndrome and whole spectrum of CG and to explore potential factors
a chronic renal failure. that contribute to the occurrence of this type of renal
Data on therapy were available on 15 HIV patients. injury. In particular, we questioned whether CG that
Only two HIV patients received a short trial of steroids, develops in HIV and non-HIV patients differs in terms
with no definable effect. Seven patients received antiviral of demographic, clinical, or pathological characteristics.
therapy for their HIV infection. Although previous studies showed idiopathic CG as be-
ing a more aggressive form of FSGS when compared
DISCUSSION with classic idiopathic FSGS [16–18], and HIVAN to
have more severe pathologic changes than matchedBy review of our renal biopsy material, we were able
to identify 18 HIVAN (HIV-associated CG) and 42 non- HAN and idiopathic FSGS controls [9], we report com-
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parative clinicopathologic and follow-up data on 60 unse- HIV patients with CG, whereas others have reported
a very low incidence of these endothelial inclusions inlected CG patients with and without HIV infection.
A comparison of demographic, clinical, and pathologi- idiopathic CG [16–18]. Because only one of five non-
HIV patients with an evidence of HCV infection andcal features of CG in HIV and non-HIV patients in our
material revealed remarkable similarities. Patients’ sex IVDA had TRIs in the endothelial cells, the high fre-
quency of TRIs in our non-HIV patients is not solelydistribution, mean age, serum creatinine, daily protein-
uria at biopsy, and most of the clinical manifestations at contributed by this subgroup of patients. In fact, the high
frequency of TRIs in our non-HIV patients is also duepresentation or at the time of biopsy were indistinguish-
able. Moreover, the same can be said about the morpho- to seven patients having associated systemic illnesses:
SLE-like disorder (3 patients), mixed connective tissuelogic expression of the disease: The extent of the glomer-
ular involvement by collapsing and sclerotic lesions as disease (1 patient), acute monoblastic leukemia (1 patient),
cerebral arteritis (1 patient), and HTLV-I infection (1well as the extent of active and chronic interstitial disease
was indistinguishable. Similarly, the probability of renal patient). A calculated positive predictive value of 0.54
TRIs for HIV infection in patients with CG is somewhatsurvival was not significantly different in HIV versus
non-HIV patients by product-limit analysis without con- lower than suggested in previous reports [9, 27]. Interest-
ingly, D’Agati and Appel suggested that TRIs are lesstrolling for other variables.
Several features of CG, however, are clearly distinct abundant in cases of HIVAN diagnosed in the late 1990s
[28]. The incidence of TRIs in our HIV patients, how-in HIV and non-HIV patients. A high prevalence of
blacks was found in the HIV group as opposed to an ever, has not changed significantly before and after 1989
(data not shown). Marked cast nephropathy with micro-almost equal distribution in non-HIV patients. Not sur-
prisingly, 72% of HIV patients had identified risk factors cystic tubular dilation was another pathological feature
more frequently observed in HIV patients, a finding con-for HIV infection, whereas only 19% of non-HIV pa-
tients revealed potential risk factors for HIV. Five non- sistent with a previous observation [9].
One additional ultrastructural feature of CG is worthHIV patients had history of IVDA and could have been
considered as having HAN, constituting only a small mentioning: Only 57% of HIV and 38% of non-HIV
cases, respectively, were considered to have diffuse ef-proportion of our non-HIV CG cases.
At presentation, the patients with CG rather fre- facement of foot processes (over 80% of glomerular cap-
illary surface). It is our impression that the effacementquently revealed flu-like illness with nonspecific respira-
tory and/or gastrointestinal symptoms. However, a his- of foot processes in this condition is less extensive than
in minimal change disease, in spite of the high level oftory of fever was more frequently noted in HIV patients.
As reported in patients with HIVAN [7], our HIV pa- proteinuria. Nevertheless, the extent of “fusion” of the
foot processes was the best predictor of proteinuria intients rarely presented with arterial hypertension (as de-
fined by the treating nephrologists). The incidence of our multiple regression analysis. Of note, two previous
studies on idiopathic CG have also characterized thehypertension was significantly lower in HIV patients
when compared with non-HIV patients (6 vs. 29% in degree of effacement as “various” [16] or “mean 80%”
of the capillary surface [17]. This peculiarity may be anon-HIV). However, considering that over 70% of all
CG patients presented with a significant degree of renal reflection of a qualitatively different pathophysiological
mechanism of podocyte injury in CG when comparedfailure, the discrepancy between the incidence of hyper-
tension and the incidence of renal failure at presentation with minimal change disease, as recently suggested by
others [29, 30].appears to exist in both groups of patients.
Only two pathological features of CG appeared with A comparison of our non-HIV patients with CG with
the data from previous studies of idiopathic CG [16–18]significantly different incidence in HIV and non-HIV
patients. The presence of TRIs in glomerular endothelial is presented in Table 7. In general, there is concordance
in all major parameters of our non-HIV CG patientscells was noted in 76% of HIV patients as compared with
29% of the non-HIV group. TRIs are thought to be a and idiopathic CG, although our patients seem to have
clinically somewhat more severe disease and were biop-morphologic “footprint” of high levels of plasma alpha-
interferon [24, 25] and have been found with high fre- sied earlier when compared with the largest of the pub-
lished series [17]. We found the lowest prevalence ofquency in patients with HIV infection [26] and HIVAN
[5, 9, 27] and, therefore, may serve as a marker of HIV blacks (57%), although still comparable to that of 61%,
in New York City [17]. In contrast to the previous studiesinfection. However, the frequency of TRIs (76%) in our
HIV patients appears much less than reported previously [16–18, 31], a slight predominance of females in the group
of non-HIV CG is seen. Importantly, a similar preva-in 92% of patients with HIVAN [9]. This relatively low
frequency of TRIs in our HIV patients does not seem lence of female gender is seen in our HIV patients, in
contrast to the previous reports on HIVAN [1, 3, 9],to be caused by “less sensitive” electron microscopy tech-
nique, as we were able to document TRIs in 29% of non- whereas a high prevalence of blacks in HIV CG is con-
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Table 7. Non-HIV CG in the context of idiopathic CG
Present study Valeri et al [17] Haas et al [18] Detwiler et al [16]
N of patients 42 43 21 16
Gender % male 45a 58 62a 69a
Race % black 57 61 86 81a
Mean age years 37.8614.2 32.2 30.469.9 41.4 619.1
Mean time to biopsy months 2.362.7 7.9
Proteinuria g/day 13.3610.6 10.2 14.369.6 13.2 67.7
Mean serum creatinine at biopsy mg/dl 5.465.3 4.2 3.862.7 3.5 63.4
Glomeruli with collapsing lesions mean % 41 52
Globally sclerosed glomeruli mean % 21 17
Marked tubular microcysts % 40 12
TRI % 29 5a 0a 6a
a Recalculated from original data for purposes of comparison
cordant. Therefore, our data suggest that HIVAN is a mixed connective tissue disease, granulomatous cerebral
arteritis, multiple myeloma, or acute monoblastic leuke-“disease of blacks” rather than “black males,” as consid-
ered previously [32]. Similar to previous suggestions that mia. Interestingly, all of these conditions appear to have
a common denominator: a major disturbance of the im-HIVAN is not caused by IVDA per se [4, 32, 33], we
confirmed that only a portion of our HIV patients (44%) mune system. In addition, at least three other non-HIV
CG cases are associated with evidence of HCV infectionand non-HIV patients (12%) had a history of IVDA.
Interestingly, all five non-HIV intravenous drug abusers and one case with HTLV-I infection. Thus, of the 42
non-HIV cases, 9 are associated with autoimmune condi-with CG on biopsy (that could also be considered as HAN)
tested positive for HCV (3 of them before the biopsy or tions or hematological neoplasia, and 4 had established
viral infections other than HIV-1 or HIV-2. In otherdialysis). In other words, a small subgroup of our non-
HIV CG patients might be interpreted as having HAN, words, as many as 31% of patients with “idiopathic” CG
appear to have important comorbidity in our material.and all of them were found to be HCV positive. Recently,
a high frequency of HCV infection in intravenous drug Data on HLA antigen frequencies in patients with CG
have not been reported. Although we observed a relativeusers with FSGS has been reported [34]. These results are
also in keeping with a recent report [35] that indicated a increase in frequencies of HLA-B18 and DR-10 in blacks
and B44 and DR4 in whites, a larger set of observations issharp decrease in the incidence of new cases of HAN as
a cause of ESRD in New York City since 1989. The lack required to test the statistical significance of these findings.
The probability of renal survival during the follow-upof FSGS in European intravenous drug addicts [36] and
a high prevalence of this form of glomerular injury in period was not significantly different overall in HIV and
non-HIV patients by product-limit analysis, although aAfrican American addicts [37–39] raises the possibility
that HAN has a stronger pathogenic link to the black tendency of worse prognosis of the renal disease in HIV
patients can be noted. Multiple Cox regression analysis,race (and possibly to HCV infection) than IVDA per se.
Similarly, the occurrence of HIVAN in HIV patients however, revealed a time-dependent effect of HIV infec-
tion on renal survival. Namely, the probability of renalwas initially attributed to factor of IVDA; however, later
observations proved this relationship to be caused by death was significantly higher in HIV patients at the
time of the biopsy, but this difference diminished in thehigh prevalence of blacks HIVAN [4, 11, 33]. It is likely
that patients diagnosed as HAN in the past are indeed perspective of long-term prognosis. Indeed, the pattern
of renal survival curves (Fig. 1) illustrates this effect, withpatients with CG diagnosed during the late, progressive
phase of the disease. the probability of renal survival becoming similar in HIV
and non-HIV patients after two years of follow-up. It isIn contrast to previous studies on idiopathic CG [16–18],
a significant proportion of our non-HIV patients had difficult to speculate on the causes of this time-dependent
effect, which can also be expressed as a beneficial effectserious concurrent medical conditions. Five black females
manifested a SLE-like disorder (2 of them died because of being HIV negative. It is likely that this difference in
survival is due, at least in part, to differences in theof their systemic illness), an association not previously
reported. Another five non-HIV patients had positive therapeutic approach to these patients. Although 62%
of our non-HIV patients were treated with steroids (withANA tests at titers higher than 1:40; thus, 10 (32%) of
our non-HIV patients had positive ANA when tested. variable effect, though), only 13% of HIV patients re-
ceived a short trial of steroids. Because steroid therapyIn previous reports, only two CG patients were positive
by antinuclear antibody test, and one patient had a lupus- has been shown to have a beneficial effect on renal func-
tion and proteinuria in some patients with HIVAN [40–43]like syndrome [16, 17]. Four other patients suffered from
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and has been associated with a full or partial response our patients has to be taken into account in assessing
renal survival curves.in 24% of our non-HIV patients, one might expect that
steroid therapy could have slowed the development of In general, our study confirms a poor prognosis of CG.
The unfavorable outcome is also demonstrated by theESRD in the non-HIV group. Although our data on the
effect of steroid therapy in non-HIV patients are not observation that half of the patients without ESRD often
had pronounced renal insufficiency at the end of theencouraging, we observed a slight but nonsignificant ben-
eficial effect of steroid therapy on renal survival in our follow-up period, and 16 patients died, 5 of them before
developing ESRD. In addition, our data indicate the possi-non-HIV patients (data not shown). On the other hand,
the probability of renal survival became quite similar in bility of recurrence of the disease in the allograft, as
reported previously by other authors [16, 23, 31, 45, 46].HIV and non-HIV patients when patients treated with
steroids were excluded from the analysis (data not shown). We were able to develop a highly significant Cox
model for the prediction of renal survival in patientsInterestingly, a review of individual serum creatinine
curves over time in 29 of our patients with an adequate with CG. Along with the time-dependent effect of HIV
infection discussed earlier in this article, extensive inter-number of creatinine values revealed a particular pattern
of progression of renal insufficiency in 12 patients (1 pa- stitial fibrosis (.20% of cortical area), high serum creati-
nine (.2 mg/dl), and high proteinuria (.8 g/day) weretient with HIV). This pattern is characterized by a high
degree of renal failure (serum creatinine .2 mg/dl) at risk factors for renal death. These predictors can be
considered “classic” in nephrology, interstitial fibrosisthe time of the biopsy, with a subsequent partial but
substantial improvement of the serum creatinine to levels representing chronic irreversible loss of renal paren-
chyma, whereas proteinuria can be interpreted as a mea-below 2 mg/dl over a few months. This sometimes sponta-
neous recovery (discussed later in this article) was fol- sure of activity of the glomerular disease process. Serum
creatinine in CG may reflect both chronic irreversiblelowed by eventual progression to ESRD or a significant
degree of chronic renal failure over several months or loss of renal function and potentially reversible renal
failure during the acute phase of the disease (as discussedyears. Nine of these 12 patients were treated with ste-
roids, but 3 of the 12 patients (1 patient with HIV infec- earlier in this article); indeed, serum creatinine corre-
lated with both the extent of interstitial fibrosis and thetion) showed this course without therapy. A similar pat-
tern of improvement and subsequent progression has frequency of glomerular collapse in our multiple regres-
sion analysis. The positive effect of the extensive collaps-been reported in a patient with HIVAN treated with
steroids [43]. It appears that a subgroup of patients with ing lesions (.20% glomeruli) on renal survival in this
multiple Cox model could be interpreted as suggestiveCG presents with an acute phase that is more likely to
benefit from steroid therapy, as suggested previously in that patients with these acute lesions may have an acute,
partially reversible form of renal injury and functionalHIVAN [42], followed by remission and eventual pro-
gression to ESRD. Whether this course represents a nat- impairment. Of note, the extent of collapsing lesions was
not a significant predictor of renal death by product-ural history of CG or is a modification of the latter
because of therapeutic interventions remains unresolved. limit analysis (data not shown). Importantly, the patient’s
race and gender were not found to predict renal survivalThe spontaneous remission of the renal failure in some
patients with CG should be taken into account when in our patients. This means that despite possible race
and gender predisposition to CG, this condition has aevaluating the potential beneficial effect of different
therapeutic regimens on the course of the disease. bad prognosis, regardless of sex and race.
The rate of decline of renal function following theRenal survival in our HIV patients with CG seems
somewhat better than previously reported for HIVAN renal biopsy, measured as a slope of the reciprocal serum
creatinine, was best predicted by the degree of daily[1, 3, 6, 10]. The relatively short time from manifestation
of renal disease to biopsy, asymptomatic stage of the proteinuria at time of the biopsy, whereas the latter
parameter best correlated with the extent of effacementHIV infection in a great proportion (up to 67%) of our
patients at biopsy and, potentially, improved manage- of podocyte foot processes.
In summary, we found that CG represents a clinico-ment of HIV patients may all have contributed to this
difference [6, 44]. We did not observe, however, a sig- pathological entity with poor prognosis. It may develop
in patients with HIV and other viral infections as wellnificant improvement of renal survival in those HIV (and
non-HIV) patients diagnosed after 1989 (data not shown). as in the course of autoimmune and hematological disor-
ders. Although CG in HIV and non-HIV patients revealsRenal survival of the non-HIV group is similar to
that previously reported in idiopathic CG [16–18]. The indistinguishable clinicopathological features, a high prev-
alence of black race, TRIs in the glomerular endothelialmedian survival of our non-HIV patients was 16 months
compared with 13 months in a previous study [17]. Again, cells, and marked cast nephropathy are more characteris-
tic of HIV-associated CG. The probability of renal sur-a shorter duration of the disease before the biopsy in
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